Stock Analysis
Viatris Inc. Common StockVTRS
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsBuy17 analystsPrice is 100% of the way from the year's low to its high.
Cash covers 11% of debt · FY 2025.
PMP Verdict
Weak fundamentals, expensive
Risks
- Valuation70
- Growth0
Weak fundamentals at a demanding price.
Market context
+2.4% today· Z 1.0σ
What's happening with VTRS
Profile
growth, profitability, financial health, moat and earnings quality lag behind.
How is each axis scored?
- Valuation70/100 · Moderate
- P/E vs own history (n/a)10/25
- FCF yield (9.2%)25/25
- P/S (1.4x)25/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (-5.4%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-0.3%)0/25
- ROE (-2.8%)0/25
- Net margin (-2.8%)0/25
- Operating margin (-0.6%)0/25
- Financial Health20/100 · Weak
- Altman Z (0.80)3/25
- Current ratio (1.38)12/25
- Interest coverage (-0.3x)0/25
- Net cash / debt (D/A 30%)5/25
- Quality46/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (-3.23)25/25
- FCF conversion (-476%)0/25
- Margin stability (σ 22.3%)6/25
- Moat38/100 · Weak
- ROIC >12% years (0/6 yrs)0/25
- Median gross margin (36.6%)13/25
- FCF-positive years (6/6 yrs)25/25
- Worst-year net margin (worst -24.6%)0/25
Risk Flags
- ⚠Altman Z 0.8 — distress-zone balance sheet
- ⚠4 loss-making years in recent history
- ⚠Interest coverage -0.3× — thin debt cushion
- ⚠Revenue shrinking 5.4%/yr
About Viatris Inc. Common Stock
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. Show more
By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Headquarters: CANONSBURG, PA · Employees: 30,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
70B+P/E (TTM)—
Price / TTM EPS (own statements)
P/FCF11.5xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield9.2%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 8.8%–29.9% · 1st pct
P/S (TTM)1.45xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 5Y history: 0.5x–1.5x · highest in history
EV/EBITDA12.5xB
Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales2.3xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E6.6xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.45xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.51B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield2.66%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio79.1%C
Grade C: HighDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-0.3%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-2.8%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-1.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-2.8%D
Grade D: LowNet Income / Revenue
Operating Margin-0.6%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin34.8%C
Grade C: AverageGross Profit / Revenue
FCF Margin13.3%C
Grade C: AverageFCF / Revenue
True FCF Margin12.1%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-5.4%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-4.9%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.2%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
20EAltman Z-Score0.80D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.38xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.83xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-0.3xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment5.7yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.85xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.11xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
46D+Piotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-3.23A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion-476.0%D
Grade D: PoorFCF / Net Income
Margin Stability22.3%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue2.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.40xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Groothuis Leo Frans Filed | Groothuis Leo Frans | Grant / award | +2.5K | |
SIMMONS DAVID S Filed | SIMMONS DAVID S | Grant / award | +2.1K | |
Enrietti Andrew Filed | Enrietti Andrew | Option exercise | -998 | |
Enrietti Andrew Filed | Enrietti Andrew | Option exercise | -25134 | |
Enrietti Andrew Filed | Enrietti Andrew | Tax withholding | -435 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Enrietti Andrew Filed | Enrietti Andrew | Option exercise | +999 | |
Enrietti Andrew Filed | Enrietti Andrew | Tax withholding | -10931 | |
Enrietti Andrew Filed | Enrietti Andrew | Option exercise | +25.1K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
38DROIC >12% Years0/6 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)36.6%C
Grade C: ModerateMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years6/6 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-24.6%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$1.18
Cash & short-term investments per share (Finnhub)
Book Value / Share$12.34
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$12.48B
Total debt obligations (short + long term)
Cash & Equiv.$1.32B
Cash and short-term investments
Net Debt$11.16B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$14.71B
Shareholders' equity (book value)
Asset / Liability1.65xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$21.35B
Current Market Capitalization
Beta0.90B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Viatris Inc. Common Stock (VTRS)
VTRS is up 2.39% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Viatris Inc. Common Stock. Altman Z-Score of 0.80 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -3.23 suggests a low likelihood of earnings manipulation. Revenue has been contracting (CAGR ≈ -5%), which weighs on the growth outlook.
- Takes ~5.7 years to repay net debt from free cash flow.
- Interest coverage of -0.3× leaves little room for earnings shocks.
- Viatris Inc. Common Stock posted a net loss in 4 of 7 available completed fiscal years (2019–2025).
- At a valuation score of 70/100, VTRS trades near the cheapest end of its own historical range.
- The stock currently yields 2.7% in dividends.
See how VTRS ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all VTRS moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 18.17 | +4.16% | 3.11 |
| Oct 15 | After-hours | 18.22 | +4.47% | 3.34 |
| Oct 8 | After-hours | 17.11 | -2.17% | -2.03 |
Frequently Asked Questions about VTRS
What is the current Viatris Inc. Common Stock (VTRS) stock price?
VTRS is trading at $18.66 at the last market close, up 2.39% on the session. PreMarketPrice tracks VTRS pre-market, intraday and after-hours prices.
Is VTRS stock a buy right now?
PreMarketPrice's quantitative model rates Viatris Inc. Common Stock's financial health at 20/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is VTRS stock overvalued?
Viatris Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 70/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Viatris Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for VTRS. The Earnings section lists recent reports and updates as dates are announced.
What sector does Viatris Inc. Common Stock operate in?
Viatris Inc. Common Stock operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Viatris Inc. Common Stock do?
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs.
About Viatris Inc. Common Stock (VTRS) Stock
Viatris Inc. Common Stock (VTRS) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Viatris Inc. Common Stock is trading at $18.66, up 2.39% on the day with a market capitalization of $21.4 billion. The financial health score for VTRS is 20/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for VTRS stock.
VTRS Stock Analysis & Key Metrics
On PreMarketPrice, you can track Viatris Inc. Common Stock (VTRS) across multiple dimensions:
- Pre-market price & movement: Real-time VTRS stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for VTRS with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Viatris Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 20/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for VTRS.
- Sector peers: Compare VTRS against 6 other healthcare stocks on key financial metrics.
Is VTRS a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Viatris Inc. Common Stock (VTRS) as an investment. The financial health score of 20/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Viatris Inc. Common Stock (VTRS) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.